BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

TolerRx, Inc. Acquires Assets For Lead Product, TRX4


10/19/2005 5:13:12 PM

CAMBRIDGE, Mass., April 4 /PRNewswire/ -- TolerRx today announces the acquisition of certain intellectual property and material assets from Diabetogen Biosciences. TolerRx has acquired access to technology under a patent application and a licensing agreement between Diabetogen and The L'Institut National de La Sante et de La Recherche Medicale (INSERM) relating to the therapeutic use of anti-CD3 antibodies in autoimmune diseases. In addition, TolerRx has acquired rights to technology and material relating to a panel of fully human anti-CD3 antibodies under a licensing agreement between Diabetogen and Abgenix, Inc. Financial terms of the agreement were not disclosed.

"The acquisition of these assets facilitates our objective to position TolerRx as the market leader with anti-CD3 products," stated Dr. Douglas J. Ringler, President and Chief Executive Officer of TolerRx. "In particular, we are dedicated to commercializing our lead product targeting CD3, TRX4, in multiple autoimmune disease indications, and this acquisition provides us with additional resources necessary to protect those markets."

About TolerRx

TolerRx is a biopharmaceutical company specializing in the discovery, development, and commercialization of novel therapies to treat patients with immune-mediated diseases. TRX4 is a humanized anti-CD3 monoclonal antibody that has completed an investigator-sponsored Phase II clinical trial in patients with new onset Type 1 diabetes. TolerRx's TRX1 is a humanized anti- CD4 monoclonal antibody that has been partnered with Genentech, Inc. and is in Phase Ib clinical development. TolerRx is also developing new products to induce immunological tolerance for the treatment of autoimmune diseases and to remove tolerance for the treatment of cancer or chronic viral diseases. For more information, please visit http://www.tolerrx.com/.

About INSERM

INSERM is the pre-eminent French biomedical research organization. INSERM's mission is to conduct research and support research enterprise in biology, medicine, and health. INSERM consists of 360 laboratories, 24 clinical centers, and 7 joint laboratories with EU and US universities. INSERM has a long tradition of working with the biomedical industry worldwide. INSERM actively seeks patent protection and grants access to its technology portfolio through licensing and ensures the availability and dissemination of its biomedical resources. INSERM's active portfolio consists of 587 patent families in biotechnology/biopharma, 508 research and development contracts, and 490 licenses. Marketed products include two HBV vaccines, pharmaceuticals, medical devices, diagnostic kits, and research tools. INSERM has been instrumental in the creation of 60 spin-off companies since 1998.

CONTACT: TolerRx, Inc. Thomas A. Shea 1-617-452-1300 tshea@tolerrx.com

TolerRx, Inc.

Contact: Thomas A. Shea of TolerRx, Inc., +1-617-452-1300,tshea@tolerrx.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES